The GRB7 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, featuring targeted disruption of the GRB7 gene. This heterogeneous pool of cells enables robust loss-of-function studies without requiring clonal isolation, and the polyclonal format captures diverse genetic modifications introduced by CRISPR/Cas9, ensuring reproducible knockout phenotypes.
The parental A-549 cell line was established from human lung adenocarcinoma and displays adherent epithelial morphology, typical of alveolar basal epithelial cells. As a widely used non-small cell lung cancer model, it retains oncogenic drivers relevant to lung tumorigenesis and is commonly employed in respiratory epithelium research and lung adenocarcinoma studies due to its origin from a primary carcinoma and retention of key oncogenic pathways.
GRB7 is a cytoplasmic adaptor protein that mediates signal transduction downstream of receptor tyrosine kinases, including ERBB2/HER2, EGFR, and IGF1R. It binds activated receptors via its SH2 domain and recruits effectors such as FAK, phosphoinositides, and Ras, coupling RTK activation to PI3K/AKT and MAPK/ERK pathways. GRB7 also regulates focal adhesion dynamics and Rho GTPase-mediated cell migration. Knockout of GRB7 abrogates adaptor-mediated signaling, impairing FAK activation, AKT phosphorylation, and ERK1/2 signaling, thereby reducing proliferation, migration, and invasion.
In A-549 cells, GRB7 knockout disrupts the signaling networks driving tumor cell motility. Loss of GRB7 impedes ERBB2- and EGFR-dependent activation of FAK and AKT, limiting directed migration and invasiveness. Since GRB7 is implicated in aggressive phenotypes across multiple carcinomas, this model provides a physiologically relevant system to study adaptor-dependent oncogenic signaling in lung adenocarcinoma, including mechanisms of metastasis and potential drug resistance. In this cellular context, GRB7 knockout serves as a powerful tool to delineate the adaptor??s contributions to pathways that are frequently dysregulated in lung cancer.
Typical applications employ western blotting for phospho-AKT and phospho-ERK, RT-qPCR for GRB7 expression, and transwell migration/invasion assays to assess altered motility. Proliferation is measured via MTT assay, while co-immunoprecipitation confirms GRB7?CERBB2 interaction, and immunofluorescence visualizes FAK redistribution. Apoptosis assays and tumor xenograft models further evaluate therapeutic vulnerabilities and metastatic potential. This polyclonal knockout cell population supports target validation, drug response profiling, and mechanistic studies of adaptor protein function. Such studies are critical for understanding GRB7-dependent mechanisms in tumor progression and for identifying therapeutic intervention points. For further inquiries, please contact Ascent Research.
